Cara Therapeutic Stock Net Income
| CARA Stock | USD 0.67 0 0.30% |
Cara Therapeutic fundamentals help investors to digest information that contributes to Cara Therapeutic's financial success or failures. It also enables traders to predict the movement of Cara Stock. The fundamental analysis module provides a way to measure Cara Therapeutic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cara Therapeutic stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -118.5 M | -112.6 M | |
| Net Loss | -116.5 M | -110.7 M | |
| Net Loss | -76.9 M | -80.8 M | |
| Net Loss | (2.19) | (2.30) | |
| Net Income Per E B T | 0.88 | 0.80 |
Cara | Net Income |
Cara Therapeutic Company Net Income Analysis
Cara Therapeutic's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Cara Therapeutic Net Income | (118.51 M) |
Most of Cara Therapeutic's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cara Therapeutic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cara Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cara Therapeutic is extremely important. It helps to project a fair market value of Cara Stock properly, considering its historical fundamentals such as Net Income. Since Cara Therapeutic's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cara Therapeutic's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cara Therapeutic's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cara Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cara Therapeutic reported net income of (118.51 Million). This is 134.73% lower than that of the Pharmaceuticals sector and 269.19% lower than that of the Health Care industry. The net income for all United States stocks is 120.76% higher than that of the company.
Cara Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cara Therapeutic's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cara Therapeutic could also be used in its relative valuation, which is a method of valuing Cara Therapeutic by comparing valuation metrics of similar companies.Cara Therapeutic is currently under evaluation in net income category among related companies.
Cara Therapeutic Institutional Holders
Institutional Holdings refers to the ownership stake in Cara Therapeutic that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cara Therapeutic's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cara Therapeutic's value.| Shares | Bank Of America Corp | 2023-12-31 | 644.8 K | Verition Fund Managegment, Llc | 2023-12-31 | 550 K | Two Sigma Advisers, Llc | 2023-12-31 | 514.2 K | Millennium Management Llc | 2023-12-31 | 467.2 K | Goldman Sachs Group Inc | 2023-12-31 | 419.7 K | Northern Trust Corp | 2023-12-31 | 391.8 K | Acadian Asset Management Llc | 2023-12-31 | 360.5 K | Stifel Financial Corp | 2023-12-31 | 313.1 K | Two Sigma Investments Llc | 2023-12-31 | 307.3 K | Blackrock Inc | 2023-12-31 | 3.6 M | Vanguard Group Inc | 2023-12-31 | 2.6 M |
Cara Fundamentals
| Return On Equity | -1.1 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (10.85) % | ||||
| Current Valuation | (18.94 M) | ||||
| Shares Outstanding | 54.67 M | ||||
| Shares Owned By Insiders | 14.58 % | ||||
| Shares Owned By Institutions | 45.48 % | ||||
| Number Of Shares Shorted | 2.58 M | ||||
| Price To Earning | 62.54 X | ||||
| Price To Book | 0.73 X | ||||
| Price To Sales | 1.99 X | ||||
| Revenue | 20.97 M | ||||
| Gross Profit | (56.14 M) | ||||
| EBITDA | (121.24 M) | ||||
| Net Income | (118.51 M) | ||||
| Cash And Equivalents | 157.51 M | ||||
| Cash Per Share | 2.93 X | ||||
| Total Debt | 43.17 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.32 X | ||||
| Book Value Per Share | 1.05 X | ||||
| Cash Flow From Operations | (92.08 M) | ||||
| Short Ratio | 3.51 X | ||||
| Earnings Per Share | (2.19) X | ||||
| Target Price | 5.23 | ||||
| Number Of Employees | 55 | ||||
| Beta | 0.7 | ||||
| Market Capitalization | 38.66 M | ||||
| Total Asset | 125.84 M | ||||
| Retained Earnings | (684.75 M) | ||||
| Working Capital | 90.57 M | ||||
| Current Asset | 108.93 M | ||||
| Current Liabilities | 5.27 M | ||||
| Net Asset | 125.84 M |
About Cara Therapeutic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cara Therapeutic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cara Therapeutic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cara Therapeutic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cara Therapeutic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cara Therapeutic's short interest history, or implied volatility extrapolated from Cara Therapeutic options trading.
Pair Trading with Cara Therapeutic
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cara Therapeutic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cara Therapeutic will appreciate offsetting losses from the drop in the long position's value.Moving together with Cara Stock
| 0.86 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.78 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.69 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
Moving against Cara Stock
| 0.48 | ZURA | Zura Bio Limited Financial Report 10th of May 2024 | PairCorr |
The ability to find closely correlated positions to Cara Therapeutic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cara Therapeutic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cara Therapeutic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cara Therapeutic to buy it.
The correlation of Cara Therapeutic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cara Therapeutic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cara Therapeutic moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cara Therapeutic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Cara Therapeutic Piotroski F Score and Cara Therapeutic Altman Z Score analysis. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Cara Stock analysis
When running Cara Therapeutic's price analysis, check to measure Cara Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutic is operating at the current time. Most of Cara Therapeutic's value examination focuses on studying past and present price action to predict the probability of Cara Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutic's price. Additionally, you may evaluate how the addition of Cara Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Cara Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Revenue Per Share 0.387 | Quarterly Revenue Growth (0.08) | Return On Assets (0.49) | Return On Equity (1.10) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.